Participants 101 129 4
metastatic colorectal cancer
Participants 150 214 5
two consecutive southern Italy cooperative oncology group trials
Participants 399 469 4
2 consecutive randomized trials in metastatic colorectal cancer (CRC).
Participants 491 752 7
Individual data of 254 patients were merged, and baseline features potentially affecting overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and occurrence of severe toxicity were analyzed by univariate and multivariate analyses
Participants 1738 1798 3
regimen was effective and well tolerated by elderly patients
